You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical Evaluation of a Resorbable Vena Cava Filter

    SBC: Adient Medical Inc.            Topic: NHLBI

    PROJECT SUMMARYClinical Evaluation of a Resorbable Inferior Vena Cava FilterPulmonary embolismPEis therd leading cause of deathclaiming the lives of at leastAmericans annuallymore than breast cancerAIDSand vehicle fatalities combinedMetallic Inferior Vena CavaIVCfilters have been proven effective in reducing PE to aboutin at risk populationshoweverthey come with a heavy post deployment pricenamely ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid Molecular Detection of Tuberculosis without PCR amplification

    SBC: SCANOGEN INC.            Topic: NIAID

    Project Summary TuberculosisTBis a major global burden that killsmillion people every yearTB mostly affects developing countriesbut the rise of multi drug and extensively drug resistant strains is a global threatIn order to control and eradicate this diseaseit is imperative to have adequate tools to detect active TB in limited resource settings and point of carePOCsettingswhich is where most TB pa ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT The development of Sanaria s Plasmodium falciparumPfsporozoiteSPZbased vaccines is receiving overwhelming global support after the publication inin Science of clinical data showingprotection against controlled human malaria infectionCHMIfollowing intravenous administration ofdoses of SanariaPfSPZ Vaccinecomposed of purifiedasepticradiation attenuatedcryopreserved PfSPZ meeting all regulat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture

    SBC: SANARIA INC.            Topic: NIAID

    Abstract An ideal tool for eliminating Plasmodium falciparumPfthe causative agent ofof all malaria deathswould be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmissionSanaria has developed two effective vaccines that are phaseclinical trialsPf sporozoiteSPZvaccine that prevents Pf blood stage infection in andgtof recipients and PfSPZ Chal ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. IND-enabling development of a biomimetic peptide drug for macular edema

    SBC: Asclepix Therapeutics, Inc.            Topic: NEI

    SummaryMacular edemaMEand diabetic macular edemaDMEwhich affects at leastmillion people in theUSare leading causes of blindness in people between the ages ofThe major problem in thesediseases is a leaky vasculaturewhich results in pooling of blood around the retinaThis blood can causeocclusion of vision as well as swelling and increased ocular pressure and detachment of the retinaThe effective the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia

    SBC: AAVOGEN INC            Topic: 102

    PROJECT SUMMARY. The skeletal muscle wasting that occurs with cancer cachexia compromises quality of life and is both directly and indirectly responsible for cancer mortalities. Tumor-derived and tumor-responsive factors as well as many therapeutics themselves contribute to the cachectic state, although nutritional support has little if any positive effect on restoring striated muscle mass or func ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Service and Software Solution for the Rigorous Design of Animal Studies

    SBC: SERALOGIX, LLC            Topic: NIDA

    The primary goal of this fast track project is to commercialize a cloud based software suite complemented with on call expert services to guide life science researchersthat may have minimal statistical and experimental designEDknowledgeto rigorously planoptimizejustifymanageand report results for complex animal studiesInadequately planned experimentse glack of randomization blinding and diversityl ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Aspirin-PC for Chemoprevention of Colorectal Cancer

    SBC: PLx Opco Inc.            Topic: NCI

    ABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies

    SBC: A&G PHARMACEUTICAL, INC.            Topic: 102

    SignificanceInnew cases of LC andrelated deaths are expected in the USOf new LC casesare non small cell lung cancerNSCLCandof these are diagnosed with metastaticlocally advancedinoperable LC with ayr survival of less thanA new approach is required to reduce the overall death rates in this devastating diseaseEfficacious therapies targeting EGFRALK and ROS translocations and vEGF are used in standar ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.

    SBC: Biomarker Strategies, LLC            Topic: 102

    Lung cancerLCis the leading cause of cancer death in the US with an estimateddeaths inNonsmall cell LC is the predominant category of the diseaseNSCLCMolecular characterization of tumors has shifted the paradigm of one drug fits allCurrentlymolecularly targeted agentsMTAsand companion diagnosticsCDxare being developed to target oncogenic drivers in signaling pathwaysand select patients most likely ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government